The Acute Effect of Hypericum Perforatum on Short-Term Memory in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-21

Study Completion Date

2018-02-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale Over-the-counter drugs containing hypericum perforatum (H. perforatum), have been argued to improve memory and sustained attention. So far, these claims have not been supported in human studies. However, previous studies used rather high dosages, and little is known about the acute effect of small dosages.

Objective We evaluated whether an acute treatment with Remotiv 500 and Remotiv 250 (500 or 250 mg of H. perforatum quantified to either 1 or 0.5 mg of hypericin) improved memory, sustained attention, as well as mood and state anxiety in healthy adults.

Method A single dosage, randomized, double blind, placebo-controlled trial was conducted with 82 student participants (33 women). Each participant received placebo in one session and one of two dosages in the other session. Order of the sessions and dosage conditions were randomized between subjects. Participants completed a battery of tasks assessing short-term memory capacity and sustained attention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Huperzine A in Treatment of Moderate to Severe TBI

NCT01676311

Traumatic Brain Injury

TERMINATED PHASE2

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

NCT04778644

CBD

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

NCT01037608

Cannabis Dependence Cannabis Abuse +2 more

COMPLETED PHASE1

Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

NCT02291536

Healthy Humans

COMPLETED NA

Effects of THC and CBD on Human Episodic Memory Function

NCT02291562

Healthy Volunteers

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subclinical Anxious Adults Nootropic Potential of Hypericum and Alprazolam Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypericum perforatum (Remotiv, 250 mg)

Group Type EXPERIMENTAL

Hypericum perforatum extract

Intervention Type DRUG

250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.

Hypericum perforatum (Remotiv, 500 mg)

Group Type EXPERIMENTAL

Hypericum perforatum extract

Intervention Type DRUG

250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypericum perforatum extract

250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy adults 18 to 40 years old.

Exclusion Criteria

* 1\. Demographics: Under 18 years of age or older than 40; pregnant or nursing women; non-fluent Hebrew speakers.

2\. Body weight: less than 50 kg and more than 90 kg (to ensure effective drug dosage).

3\. Mental health: Diagnosed with any DSM-V disorder (including ADHD, learning disabilities). These DSM-V disorders may be included in the research: sexual dysfunctions, sleeping disorders and mild-moderate anxiety disorders.

4\. Any motor disability hampering a participant's ability to perform the experimental task.

5\. Consumption of any psychoactive substance within the last 72 hours. 6. Ongoing medical problems or use of any substances (e.g., other prescribed medications) which may interact negatively with any of the three drugs used in the experiment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes